Page last updated: 2024-10-25

cilostamide and Multiple Sclerosis

cilostamide has been researched along with Multiple Sclerosis in 1 studies

cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure

Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sunke, R1
Bankala, R1
Thirupataiah, B1
Ramarao, EVVS1
Kumar, JS1
Doss, HM1
Medishetti, R1
Kulkarni, P1
Kapavarapu, RK1
Rasool, M1
Mudgal, J1
Mathew, JE1
Shenoy, GG1
Parsa, KVL1
Pal, M1

Other Studies

1 other study available for cilostamide and Multiple Sclerosis

ArticleYear
InCl
    European journal of medicinal chemistry, 2019, Jul-15, Volume: 174

    Topics: Animals; Arthritis; Cyclic Nucleotide Phosphodiesterases, Type 4; Encephalomyelitis, Autoimmune, Exp

2019